Resmed Acquires Noctrix Health to Enter Restless Legs Syndrome Market
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
Tag: RLS
All
Latest
All
Latest
New AASM Guidelines Overhaul Restless Legs Syndrome Treatment
The updated guideline emphasizes iron evaluation and supplementation while recommending against the use of dopamine agonists due to risks of symptom worsening.
All
LatestSorry, No Posts Found
CDC Changes Opioid Prescribing Guidelines
The 2022 CDC Opioid Prescribing Guidelines released on November 3, 2022, replaced earlier guidelines that had led to confusion, misinterpretation, and faulty application by medical providers, according to a statement from the RLS Foundation.
Read More
Research Needs Rodent Models of Restless Legs Syndrome, But Assessing RLS in Mice Is Tricky
The International Restless Legs Syndrome Study Group publishes a new guideline on construct validity of rodent models of RLS.
Read More
Restless Legs Syndrome Patients See 61% Decrease in Sleep Problems When Taking Pycnogenol Extract
A new study found Pycnogenol French maritime pine bark extract to significantly relieve and prevent symptoms associated with restless legs syndrome.
Read More
RLS Foundation Study: Restless Legs Syndrome Takes High Toll on Health
In ODYSSEY II, 2,745 people with confirmed RLS completed a survey about RLS diagnosis and severity, associated medical conditions, treatments, and medical care.
Read More
Don’t Light the Fuse of Restless Legs Syndrome with Dopamine Agonists
Twenty percent of restless legs syndrome patients are already on higher-than-recommended doses of dopamine agonists, says John Winkelman, MD, PhD.
Read More
Sleep Apnea Drug Candidate Developer Incannex to Acquire RLS Therapy Candidate Developer APIRx
The acquisition of APIRx will significantly strengthen Incannex’s position with regard to cannabinoid and psychedelic treatment development.
Read More
COVID Pandemic Linked to Worsening Restless Legs Syndrome
Ben Wipper discusses the study “Restless legs syndrome severity in the National RLS Opioid Registry during the COVID-19 pandemic.”
Read MoreAzurity Pharmaceuticals Acquires Arbor Pharmaceuticals
Azurity Pharmaceuticals Inc has acquired Arbor Pharmaceuticals Inc, marketers of the restless legs syndrome drug Horizant.
Read More
Relaxis for RLS Is Discontinued
Relaxis, a vibratory counterstimulation device for RLS patients that was FDA cleared in 2014, is no longer filling new prescriptions.
Read More